BioSpace News Archive

In response to the shortage of molybdenum-99 that the nuclear medicine community faces in November 2022, the world’s major processing facilities and reactors confirm the details of their plans to continue serve the 40 million patients a year who undergo technetium-99m based SPECT scans to diagnose life-critical diseases.

According to Vision Research Reports, the global medical enzyme technology market size was valued at US$ 4.37 billion in 2021 and it is expected to hit around US$ 7.38 billion by 2030. It is projected to expand at a CAGR of 6% during the forecast period 2022-2030.

The global mycoplasma testing market size was valued at USD 761.51 million in 2021 and it is predicted to surpass around USD 2.32 billion by 2030 with a CAGR of 13.18% from 2022 to 2030.

The oncolytic virus immunotherapy market reached value at US$ 108 Million in 2020 and predicted to hit US$ 2.4 billion by 2030 with expanding CAGR of 32% from 2021 to 2030.

The global glioblastoma multiforme treatment market size is expected to hit around US$ 10.2 billion by 2030, according to a new report by Vision Research Reports.

The global immunotherapy drugs market size was estimated at USD 110.74 billion in 2021 and it is expected to surpass around USD 200.62 billion by 2030, poised to grow at a CAGR of 6.83% from 2022 to 2030

AbbVie (NYSE: ABBV) today announced it would present new data across its rheumatology portfolio, including RINVOQ® (upadacitinib) for rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis, and SKYRIZI® (risankizumab) for psoriasis and psoriatic arthritis at the American College of Rheumatology’s annual meeting (ACR Convergence 2022).

Procaps Group, a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced that it expects to report its results for the third quarter ended September 30, 2022, after the market closes on Monday, November 14, 2022.

ARS Pharmaceuticals, Inc. announced the closing of its merger with Silverback Therapeutics, Inc.

Beyond Air, Inc. announced financial results for its second fiscal quarter ended September 30, 2022.